Major Depressive Disorder in Adolescents
Conditions
Interventions
Therapy Group:Intranasal Dexmedetomidine combined with Intravenous Esketamine
Sponsors
Guabgzhou First People‘s Hospital
Eligibility
Sex/Gender
All
Age
12 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Aged 12-18 years (inclusive), any sex; 2. Meet DSM-5 criteria for Major Depressive Disorder (MDD), as assessed by a psychiatrist; 3. Current episode duration >= 2 weeks; 4. If suicidal ideation is present, the risk must be classified as non-imminent on the Columbia-Suicide Severity Rating Scale (C-SSRS) (i.e., no immediate high-risk plan or means); 5. Prior antidepressant use is permitted, provided the dosage has been stable for >= 14 days.
Exclusion criteria
Exclusion criteria: 1. Comorbid bipolar disorder, schizophrenia, or other psychiatric disorders; 2. Severe hypertension, bradycardia, conduction block, or recent serious heart disease; 3. Craniocerebral injury or epilepsy; 4. Moderate to severe hepatic/renal impairment; 5. Allergy to anesthetic drugs; 6. Patients currently taking three or more psychotropic medications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Depression Rating Scale (HAMD-24) Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hamilton Anxiety Rating Scale (HAMA) Score;Columbia-Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation Score;Behavior Rating Inventory of Executive Function (BRIEF) Score;Resting-state and task-state EEG alpha power and alpha/theta ratio;Pittsburgh Sleep Quality Index (PSQI);Vineland Adaptive Behavior Scales (VABS) Score;Adverse Event (AE) Incidence; | — |
Countries
China
Contacts
Public ContactYanlu Ying
Guabgzhou First People‘s Hospital
Outcome results
None listed